News & Events
-
AACR 2024
Cypre is proud to present our latest data with our partners at Charles River in a poster on Tuesday, April 9th at 9am-noon in Section 28 (Poster 23, Abstract 4703) and a Spotlight Presentation on Sunday, April 7, 1:30 (Sails Pavilion, Spotlight Theater B). See you there!
-
Eureka Blog Post
November 30, 2023: Cypre Founder and CEO, Kolin Hribar, PhD, is interviewed by the Eureka Blog to discuss revolutionizing oncology drug development with translationally relevant 3D tumor models.
-
Q2 2023 Press Release
Cypre announces its 3D in vitro tumor models services and landmark publication detailing the platform for screening targeted and immunotherapy compounds and assessing novel immuno-modulatory insights.
-
AACR 2023
Cypre and Charles River present poster #1722 titled "KRAS, BRAF, BRCA1 and EGFR Mutation-Specific Panels Using Hydrogel-Based 3D In Vitro Tumor Models" on April 17, 9:00 AM - 12:30 PM.
-
Q1 2023 Press Release
Charles River launches press release ahead of AACR for its end-to-end Oncology Discovery capabilities, with the Cypre platform featured as a critical step for in vitro pharmacology and drug screening prior to IND.
-
SITC 2022
Cypre presents two posters on the Cypre Tumor Panels for immunotherapy screening (#299) 3D in vitro Tumor microenvironment models for screening CAR-T cell therapy efficacy. (#1447) A 30 PDX Panel of 3D in vitro tumor models identifies responders to Pembrolizumab and Solitomab.
-
AACR 2022
Cypre and Charles River present poster #1880 titled “High throughput screening of 30 PDX cell lines in a 3D ECM hydrogel platform, incorporating tumor, stroma and immune components to demonstrate simultaneous investigation of multiple anti-tumor modalities” on April 11, 1:30 - 5:00 PM.
January 8th, 2022
Cypre participates in Endpoints Webinar sponsored by Charles River titled “Changing the game: An examination of cutting-edge novel oncology screening tools.”
November 4th, 2021
Cypre and Charles River present poster #943 at the society of immunotherapy conference (sitc): “3D in vitro tumor model platform rapidly assays immunotherapy efficacy with high content imaging and downstream phenotypic changes with flow cytometry and cytokine analysis.”
November 10th, 2021
May 12, 2021
Cypre presents at the SelectScience® Virtual Cancer and Immunology Research Summit 2021 with Charles River highlighting our 3d tumor model platform for PDX in vitro modeling and cancer drug screening. View summit.
Cypre presents webinar with Charles River highlighting the synergy of our platform with pdx models for anticancer and immunotherapy drug screening. Watch webinar.
April 13, 2021
April 10, 2021
Cypre presents poster #3184 with Charles River at the AACR Annual Meeting 2021. View poster.
Cypre announces strategic partnership with Charles River for oncology and immuno-oncology drug discovery screening services. View press release.
January 28, 2021
September 2020
Cypre initiates validation on additional patient-derived solid tumors with its 3D tumor model platform.
March, 2020
Cypre validates its 3D tumor model platform with patient-derived NSCLC for immunotherapy screening.
Cypre completes several additional pilots with top pharmaceuticals, biotechs and drug discovery providers.
July, 2019
Cypre presents data in an oral mini-symposium presentation at AACR 2019 in collaboration with Genentech. View abstract.
April, 2019
Cypre presents poster at SLAS showcasing synergy of 3D hydrogel technology with high content analysis in collaboration with Molecular Devices.
February, 2019
January, 2019
Cypre 3D Hydrogel Technology short-listed as one of The Top Drug Discovery Tools of 2018 by SelectScience.
Cypre publishes peer-reviewed manuscript in Molecular Cancer Therapeutics in collaboration with Cedars Sinai Medical Center, demonstrating ex vivo growth and drug assays using patient-derived tumors. View abstract.
January, 2019
January, 2018
Cypre invited to speak at Hanson-Wade’s Tumor Models San Francisco Conference. View event.
February, 2017
Cypre receives seed funding.
April, 2016
Cypre and Cedars-Sinai Medical Center sign collaboration agreement to assay patient tumors with drug compounds in Cypre 3D Platform.
Cypre founded and joins MBC BioLabs (formerly QB3@953), San Francisco’s premier biotech incubator.
January, 2016
Cypre and Charles River announce the launch of the Cypre 30 PDX Panel for high-content screening of targeted and immunotherapy.